<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04150861</url>
  </required_header>
  <id_info>
    <org_study_id>000152</org_study_id>
    <nct_id>NCT04150861</nct_id>
  </id_info>
  <brief_title>Rekovelle PK Trial in Chinese Women</brief_title>
  <official_title>An Open-label Trial Investigating the Pharmacokinetics of FE 999049 Given as a Single Subcutaneous Dose in Gonadotropin Down-regulated Healthy Chinese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      FE 999049 is a gonadotropin preparation containing recombinant human follicle stimulating&#xD;
      hormone (rhFSH) under development by Ferring Pharmaceuticals. It is intended for controlled&#xD;
      ovarian stimulation for the development of multiple follicles in women undergoing assisted&#xD;
      reproductive technologies (ART) such as in vitro fertilisation (IVF) or intracytoplasmic&#xD;
      sperm injection (ICSI) cycle. In previous trials the exposure to and dose proportionality of&#xD;
      FE 999049 in a clinically relevant dose range in Caucasian and Japanese healthy women have&#xD;
      been shown to be very similar. This is a trial in healthy Chinese women investigating the&#xD;
      pharmacokinetics, safety, and tolerability of a single subcutaneous dose of FE 999049.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2019</start_date>
  <completion_date type="Actual">December 16, 2019</completion_date>
  <primary_completion_date type="Actual">November 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Serum Concentration-time Curve From Dosing to Infinity (AUC)</measure>
    <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
    <description>Area under the concentration-time curve from dosing to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Serum Concentration-time Curve From Dosing up to Time t (AUCt)</measure>
    <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
    <description>AUCt is defined as the area under the serum concentration-time curve from dosing up to time t, where t is the last time point at which the concentration is above the lower limit of quantification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Serum Concentration Observed (Cmax)</measure>
    <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
    <description>Maximum concentration observed in serum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Observed Serum Concentration (Tmax)</measure>
    <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
    <description>Time of maximum observed concentration in serum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Systemic Clearance (CL/F)</measure>
    <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution Associated With the Terminal Phase (VZ/F)</measure>
    <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (t½)</measure>
    <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Changes in Electrocardiogram (ECG)</measure>
    <time_frame>At screening, on Day -1, at 12, 24, 48 hours postdose, and at the follow-up visit (Day 11)</time_frame>
    <description>Number of participants with clinically significant abnormal changes in ECG are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Changes in Vital Signs</measure>
    <time_frame>At screening, on Day -1, at 12, 24, 48 hours postdose, and at the follow-up visit (Day 11)</time_frame>
    <description>Number of participants with clinically significant abnormal changes in vital signs (systemic blood pressures, heart rate and body temperature) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Findings in Laboratory Parameters</measure>
    <time_frame>At screening, on Day -1 and Day 3, and at the follow-up visit (Day 11)</time_frame>
    <description>Number of participants with clinically significant abnormal findings in laboratory parameters (clinical chemistry, haematology, urinalysis) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Type of AEs</measure>
    <time_frame>From signed informed consent until the end-of-trial visit (Day 28)</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical trial. Number of participants with any AE (serious or non-serious) and type of AEs ( mild, moderate, severe) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Injection Site Reactions</measure>
    <time_frame>Immediately, 30 minutes, and 24 hours after administration</time_frame>
    <description>The injection site reactions (redness, pain, itching, swelling, and bruising) will be assessed by the investigator after injection, 30 minutes, and 24 hours after administration of the IMP. Each injection site reaction will be assessed as none, mild, moderate, or severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-induced Anti-follicle-stimulating Hormone (Anti-FSH) Antibodies</measure>
    <time_frame>On Day 1 predose, Day 7, and Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Follitropin delta 12 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single subcutaneous abdominal injection of Follitropin delta 12 μg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Follitropin delta 18 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single subcutaneous abdominal injection of Follitropin delta 18 μg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Follitropin delta 24 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single subcutaneous abdominal injection of Follitropin delta 24 μg on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin Delta</intervention_name>
    <description>Solution for Injection, subcutaneous administration</description>
    <arm_group_label>Follitropin delta 12 μg</arm_group_label>
    <arm_group_label>Follitropin delta 18 μg</arm_group_label>
    <arm_group_label>Follitropin delta 24 μg</arm_group_label>
    <other_name>REKOVELLE</other_name>
    <other_name>FE 999049</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female of Chinese origin, with two ethnic Chinese parents and four ethnic Chinese&#xD;
             grandparents 21-40 years of age (both inclusive)&#xD;
&#xD;
          -  Willing to stop using combined oral contraceptives (COC) in relation to the first&#xD;
             DECAPEPTYL Depot administration on Day -28&#xD;
&#xD;
          -  Agrees to use a double barrier method of contraception between Day -63 and Day 28, if&#xD;
             not abstinent. A double barrier method of contraception should also be used after Day&#xD;
             28 until menses resumes or until another contraceptive method has been established&#xD;
&#xD;
          -  Normal menstrual cycles with a range of 24-35 days in the absence of oral&#xD;
             contraceptives&#xD;
&#xD;
          -  Serum FSH less than equal to (≤)5 IU/L on Day -3 and Day -1&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 -25 kg/m^2 (both inclusive)&#xD;
&#xD;
          -  Negative serology for human immunodeficiency virus (HIV) antibody, hepatitis B&#xD;
             (surface antigen), hepatitis C antibody, and syphilis bacteria&#xD;
&#xD;
          -  Healthy according to medical history, physical examination, gynaecological&#xD;
             examination, ECG, blood pressure, and laboratory profile of blood and urine&#xD;
&#xD;
          -  Negative urine drug screen and alcohol breath test at screening and on Day -1&#xD;
&#xD;
          -  Non-smoker or light smoker (≤ 5 cigarettes/day) for at least 6 months prior to trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence or a history of clinically significant diseases of the renal, hepatic,&#xD;
             gastrointestinal, cardiovascular, or musculoskeletal systems, or presence or history&#xD;
             of clinically significant reproductive, psychiatric, immunological, endocrine or&#xD;
             metabolic diseases&#xD;
&#xD;
          -  Cancer within the last 5 years except for adequately managed basal cell carcinoma and&#xD;
             squamous cell carcinoma of the skin&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Current or a history of endocrine abnormalities such as hyperprolactinaemia,&#xD;
             polycystic ovary syndrome or other ovarian dysfunction, tumours of the pituitary gland&#xD;
             or hypothalamus, thyroid or adrenal disease&#xD;
&#xD;
          -  Clinically significant findings on the trans-vaginal ultrasound, cytology,&#xD;
             gynaecological or breast examination at screening or on Day -1 including ovarian cysts&#xD;
             or tumours of the ovaries or uterus&#xD;
&#xD;
          -  Contraindications for the use of gonadotropins and gonadotropin-releasing hormone&#xD;
             (GnRH) agonists&#xD;
&#xD;
          -  Previously treated with gonadotropins within the last 6 months prior to screening&#xD;
&#xD;
          -  History within the last two years or current abuse of alcohol or drugs&#xD;
&#xD;
          -  Presence or history of severe allergy or anaphylactic reactions&#xD;
&#xD;
          -  Intake of prescribed medication, over-the-counter (OTC) medication, or herbal&#xD;
             medicines, with the exceptions of COC, cromoglycate, and paracetamol according to the&#xD;
             labelling, within 2 weeks or 5 half-lives of the drug, whichever is longer, prior to&#xD;
             first dose of DECAPEPTYL Depot. Topical treatments of bacterial or fungal infection&#xD;
             are allowed if stopped before first dose of IMP&#xD;
&#xD;
          -  Intake of any non-registered investigational drug within the last 12 weeks preceding&#xD;
             screening, or longer if judged by the investigator to possibly influence the outcome&#xD;
             of the current trial&#xD;
&#xD;
          -  High daily consumption of caffeine-containing beverages (e.g. more than five cups of&#xD;
             coffee or equivalent) with a risk of withdrawal symptoms arising during the trial that&#xD;
             may confound the safety evaluation&#xD;
&#xD;
          -  Blood donation or major blood loss (greater than equal to [≥]500 mL) within the last 8&#xD;
             weeks, or plasma donation with the last 4 weeks preceding the first day of IMP dosing&#xD;
&#xD;
          -  Current non-smokers or light smoker with a history of long-term, heavy smoking (&gt;10&#xD;
             pack-years)&#xD;
&#xD;
          -  Previously dosed in this trial&#xD;
&#xD;
          -  Mental incapacity or language barrier precluding adequate understanding or&#xD;
             co-operation&#xD;
&#xD;
          -  Considered by the investigator to be unsuitable to participate in the trial for any&#xD;
             other reason&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Hospital Affiliated to Nanjing Medical University Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <results_first_submitted>December 1, 2020</results_first_submitted>
  <results_first_submitted_qc>December 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 24, 2020</results_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>In vitro fertilisation</keyword>
  <keyword>Controlled ovarian stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT04150861/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT04150861/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at one site in China between June 2019 to December 2019.</recruitment_details>
      <pre_assignment_details>A total of 133 subjects were screened, wherein, 24 subjects met the eligibility criteria and were randomized to the investigational medicinal product (IMP): 8 subjects each were exposed to Follitropin Delta (FE 999049) 12 μg, 18 μg and 24 μg, respectively. All the randomized subjects completed the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Follitropin Delta (FE 999049) 12 μg</title>
          <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
        </group>
        <group group_id="P2">
          <title>Follitropin Delta (FE 999049) 18 μg</title>
          <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
        </group>
        <group group_id="P3">
          <title>Follitropin Delta (FE 999049) 24 μg</title>
          <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The full analysis set (FAS) comprised data from all dosed subjects. Subjects were analyzed according to the actual dose received.</population>
      <group_list>
        <group group_id="B1">
          <title>Follitropin Delta (FE 999049) 12 μg</title>
          <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
        </group>
        <group group_id="B2">
          <title>Follitropin Delta (FE 999049) 18 μg</title>
          <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
        </group>
        <group group_id="B3">
          <title>Follitropin Delta (FE 999049) 24 μg</title>
          <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="6.0"/>
                    <measurement group_id="B2" value="29.5" spread="6.7"/>
                    <measurement group_id="B3" value="25.4" spread="4.6"/>
                    <measurement group_id="B4" value="27.8" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.2" spread="1.6"/>
                    <measurement group_id="B2" value="20.7" spread="1.9"/>
                    <measurement group_id="B3" value="22.0" spread="2.3"/>
                    <measurement group_id="B4" value="21.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Serum Concentration-time Curve From Dosing to Infinity (AUC)</title>
        <description>Area under the concentration-time curve from dosing to infinity.</description>
        <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
        <population>The per-protocol (PP) analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-time Curve From Dosing to Infinity (AUC)</title>
          <description>Area under the concentration-time curve from dosing to infinity.</description>
          <population>The per-protocol (PP) analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" spread="44.3"/>
                    <measurement group_id="O2" value="62.9" spread="19.7"/>
                    <measurement group_id="O3" value="83.1" spread="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Serum Concentration-time Curve From Dosing up to Time t (AUCt)</title>
        <description>AUCt is defined as the area under the serum concentration-time curve from dosing up to time t, where t is the last time point at which the concentration is above the lower limit of quantification.</description>
        <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
        <population>The PP analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-time Curve From Dosing up to Time t (AUCt)</title>
          <description>AUCt is defined as the area under the serum concentration-time curve from dosing up to time t, where t is the last time point at which the concentration is above the lower limit of quantification.</description>
          <population>The PP analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="38.0"/>
                    <measurement group_id="O2" value="56.6" spread="18.7"/>
                    <measurement group_id="O3" value="74.6" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Serum Concentration Observed (Cmax)</title>
        <description>Maximum concentration observed in serum.</description>
        <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
        <population>The PP analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration Observed (Cmax)</title>
          <description>Maximum concentration observed in serum.</description>
          <population>The PP analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.388" spread="26.5"/>
                    <measurement group_id="O2" value="0.677" spread="29.1"/>
                    <measurement group_id="O3" value="0.825" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Maximum Observed Serum Concentration (Tmax)</title>
        <description>Time of maximum observed concentration in serum.</description>
        <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
        <population>The PP analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Serum Concentration (Tmax)</title>
          <description>Time of maximum observed concentration in serum.</description>
          <population>The PP analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="16.0" upper_limit="36.0"/>
                    <measurement group_id="O2" value="24.0" lower_limit="16.0" upper_limit="48.0"/>
                    <measurement group_id="O3" value="24.0" lower_limit="24.0" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Systemic Clearance (CL/F)</title>
        <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
        <population>The PP analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Systemic Clearance (CL/F)</title>
          <population>The PP analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
          <units>Liter/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.301" spread="46.6"/>
                    <measurement group_id="O2" value="0.286" spread="19.7"/>
                    <measurement group_id="O3" value="0.289" spread="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution Associated With the Terminal Phase (VZ/F)</title>
        <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
        <population>The PP analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution Associated With the Terminal Phase (VZ/F)</title>
          <population>The PP analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
          <units>Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="19.5"/>
                    <measurement group_id="O2" value="20.8" spread="43.5"/>
                    <measurement group_id="O3" value="25.4" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life (t½)</title>
        <time_frame>At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose</time_frame>
        <population>The PP analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (t½)</title>
          <population>The PP analysis set comprised data from all dosed subjects except data excluded as a result of major protocol deviations. Subjects were analyzed according to the actual dose received.</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" spread="47.5"/>
                    <measurement group_id="O2" value="50.5" spread="43.5"/>
                    <measurement group_id="O3" value="60.9" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Abnormal Changes in Electrocardiogram (ECG)</title>
        <description>Number of participants with clinically significant abnormal changes in ECG are presented.</description>
        <time_frame>At screening, on Day -1, at 12, 24, 48 hours postdose, and at the follow-up visit (Day 11)</time_frame>
        <population>The safety analysis set comprised data from all dosed subjects and was used for safety analysis. The safety analysis set was identical to the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormal Changes in Electrocardiogram (ECG)</title>
          <description>Number of participants with clinically significant abnormal changes in ECG are presented.</description>
          <population>The safety analysis set comprised data from all dosed subjects and was used for safety analysis. The safety analysis set was identical to the FAS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Abnormal Changes in Vital Signs</title>
        <description>Number of participants with clinically significant abnormal changes in vital signs (systemic blood pressures, heart rate and body temperature) are presented.</description>
        <time_frame>At screening, on Day -1, at 12, 24, 48 hours postdose, and at the follow-up visit (Day 11)</time_frame>
        <population>The safety analysis set comprised data from all dosed subjects and was used for safety analysis. The safety analysis set was identical to the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormal Changes in Vital Signs</title>
          <description>Number of participants with clinically significant abnormal changes in vital signs (systemic blood pressures, heart rate and body temperature) are presented.</description>
          <population>The safety analysis set comprised data from all dosed subjects and was used for safety analysis. The safety analysis set was identical to the FAS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Abnormal Findings in Laboratory Parameters</title>
        <description>Number of participants with clinically significant abnormal findings in laboratory parameters (clinical chemistry, haematology, urinalysis) are presented.</description>
        <time_frame>At screening, on Day -1 and Day 3, and at the follow-up visit (Day 11)</time_frame>
        <population>The safety analysis set comprised data from all dosed subjects and was used for safety analysis. The safety analysis set was identical to the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormal Findings in Laboratory Parameters</title>
          <description>Number of participants with clinically significant abnormal findings in laboratory parameters (clinical chemistry, haematology, urinalysis) are presented.</description>
          <population>The safety analysis set comprised data from all dosed subjects and was used for safety analysis. The safety analysis set was identical to the FAS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Chemistry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haematology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinalysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs) and Type of AEs</title>
        <description>An AE is any untoward medical occurrence in a participant participating in a clinical trial. Number of participants with any AE (serious or non-serious) and type of AEs ( mild, moderate, severe) are presented.</description>
        <time_frame>From signed informed consent until the end-of-trial visit (Day 28)</time_frame>
        <population>The safety analysis set comprised data from all dosed subjects and was used for safety analysis. The safety analysis set was identical to the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Type of AEs</title>
          <description>An AE is any untoward medical occurrence in a participant participating in a clinical trial. Number of participants with any AE (serious or non-serious) and type of AEs ( mild, moderate, severe) are presented.</description>
          <population>The safety analysis set comprised data from all dosed subjects and was used for safety analysis. The safety analysis set was identical to the FAS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse events (AEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Injection Site Reactions</title>
        <description>The injection site reactions (redness, pain, itching, swelling, and bruising) will be assessed by the investigator after injection, 30 minutes, and 24 hours after administration of the IMP. Each injection site reaction will be assessed as none, mild, moderate, or severe.</description>
        <time_frame>Immediately, 30 minutes, and 24 hours after administration</time_frame>
        <population>The safety analysis set comprised data from all dosed subjects and was used for safety analysis. The safety analysis set was identical to the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Injection Site Reactions</title>
          <description>The injection site reactions (redness, pain, itching, swelling, and bruising) will be assessed by the investigator after injection, 30 minutes, and 24 hours after administration of the IMP. Each injection site reaction will be assessed as none, mild, moderate, or severe.</description>
          <population>The safety analysis set comprised data from all dosed subjects and was used for safety analysis. The safety analysis set was identical to the FAS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-induced Anti-follicle-stimulating Hormone (Anti-FSH) Antibodies</title>
        <time_frame>On Day 1 predose, Day 7, and Day 28</time_frame>
        <population>The safety analysis set comprised data from all dosed subjects and was used for safety analysis. The safety analysis set was identical to the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Follitropin Delta (FE 999049) 12 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Follitropin Delta (FE 999049) 18 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Follitropin Delta (FE 999049) 24 μg</title>
            <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-induced Anti-follicle-stimulating Hormone (Anti-FSH) Antibodies</title>
          <population>The safety analysis set comprised data from all dosed subjects and was used for safety analysis. The safety analysis set was identical to the FAS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signed informed consent until the end-of-trial visit (Day 28)</time_frame>
      <desc>A treatment-emergent AE was any AE occurring after administration of IMP and within the time of residual drug effect, or a pre-treatment AE or pre-existing medical condition that worsened in intensity after start of IMP and within the time of residual drug effect. Only treatment-emergent AEs are presented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Follitropin Delta (FE 999049) 12 μg</title>
          <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 12 μg on Day 1 of the Treatment Period.</description>
        </group>
        <group group_id="E2">
          <title>Follitropin Delta (FE 999049) 18 μg</title>
          <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 18 μg on Day 1 of the Treatment Period.</description>
        </group>
        <group group_id="E3">
          <title>Follitropin Delta (FE 999049) 24 μg</title>
          <description>Participants received single subcutaneous abdominal injection of Follitropin Delta 24 μg on Day 1 of the Treatment Period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Smear cervix abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Compliance</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

